Scott GK - Search Results

1

Rapid alteration of microRNA levels by histone deacetylase inhibition.

Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Scott GK, et al. Cancer Res. 2006 Feb 1;66(3):1277-81. doi: 10.1158/0008-5472.CAN-05-3632. Cancer Res. 2006. PMID: 16452179 Free article.

2

Molecular lesions involved in the progression of a human breast cancer.

Liu E, Dollbaum C, Scott G, Rochlitz C, Benz C, Smith HS. Liu E, et al. Oncogene. 1988 Sep;3(3):323-7. Oncogene. 1988. PMID: 2849743

3

Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3.

Guerra-Vladusic FK, Scott G, Weaver V, Vladusic EA, Tsai MS, Benz CC, Lupu R. Guerra-Vladusic FK, et al. Int J Oncol. 1999 Nov;15(5):883-92. doi: 10.3892/ijo.15.5.883. Int J Oncol. 1999. PMID: 10536169

4

Preferential oxidation of zinc finger 2 in estrogen receptor DNA-binding domain prevents dimerization and, hence, DNA binding.

Whittal RM, Benz CC, Scott G, Semyonov J, Burlingame AL, Baldwin MA. Whittal RM, et al. Biochemistry. 2000 Jul 25;39(29):8406-17. doi: 10.1021/bi000282f. Biochemistry. 2000. PMID: 10913246

5

Age-dependent changes in breast cancer hormone receptors and oxidant stress markers.

Quong J, Eppenberger-Castori S, Moore D 3rd, Scott GK, Birrer MJ, Kueng W, Eppenberger U, Benz CC. Quong J, et al. Among authors: scott gk. Breast Cancer Res Treat. 2002 Dec;76(3):221-36. doi: 10.1023/a:1020886801674. Breast Cancer Res Treat. 2002. PMID: 12462383

6

Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen.

Scott GK, Marden C, Xu F, Kirk L, Benz CC. Scott GK, et al. Mol Cancer Ther. 2002 Apr;1(6):385-92. Mol Cancer Ther. 2002. PMID: 12477051

7

Essential cysteine-alkylation strategies to monitor structurally altered estrogen receptor as found in oxidant-stressed breast cancers.

Meza JE, Scott GK, Benz CC, Baldwin MA. Meza JE, et al. Among authors: scott gk. Anal Biochem. 2003 Sep 1;320(1):21-31. doi: 10.1016/s0003-2697(03)00296-3. Anal Biochem. 2003. PMID: 12895466

8

Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.

Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U, Benz CC. Zhou Y, et al. Among authors: scott gk. Int J Biochem Cell Biol. 2005 May;37(5):1130-44. doi: 10.1016/j.biocel.2004.09.006. Int J Biochem Cell Biol. 2005. PMID: 15743683

9

Clinical development of histone deacetylase inhibitors as anticancer agents.

Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Drummond DC, et al. Among authors: scott gk. Annu Rev Pharmacol Toxicol. 2005;45:495-528. doi: 10.1146/annurev.pharmtox.45.120403.095825. Annu Rev Pharmacol Toxicol. 2005. PMID: 15822187 Review.

10

Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.

Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Kirpotin DB, Benz CC. Drummond DC, et al. Clin Cancer Res. 2005 May 1;11(9):3392-401. doi: 10.1158/1078-0432.CCR-04-2445. Clin Cancer Res. 2005. PMID: 15867240

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters